Lista de obras - Jeremie Guedj - Dominio Público Uruguay

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

artículo científico publicado en 2014

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

artículo científico publicado en 2013

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

artículo científico publicado en 2018

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

artículo científico publicado en 2022

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

scientific article published on 05 July 2019

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

scientific article published in 2021

Can we use viral kinetic models to individualize treatment?

artículo científico publicado en 2015

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

artículo científico publicado en 2016

Design evaluation and optimization for models of hepatitis C viral dynamics.

artículo científico publicado en 2011

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults

artículo científico publicado en 2015

Determining Ribavirin's mechanism of action against Lassa virus infection

artículo científico publicado en 2017

Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection.

artículo científico publicado en 2012

Dose regimen of favipiravir for Ebola virus disease

artículo científico publicado en 2014

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

artículo científico publicado en 2015

Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates

artículo científico publicado en 2021

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

artículo científico publicado en 2016

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

artículo científico publicado en 2018

Ebola virus dynamics in mice treated with favipiravir

artículo científico publicado en 2015

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

artículo científico publicado en 2013

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

artículo científico publicado en 2016

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

artículo científico publicado en 2016

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

artículo científico publicado en 2016

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

artículo científico publicado en 2017

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

artículo científico publicado en 2011

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

artículo científico publicado en 2012

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

artículo científico publicado en 2020

Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease

artículo científico publicado en 2014

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection

artículo científico publicado en 2012

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

scientific article published on 07 January 2021

Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted

artículo científico publicado en 2014

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

artículo científico publicado en 2012

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

artículo científico publicado en 2013

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

artículo científico publicado en 2014

Modelling hepatitis C therapy--predicting effects of treatment

artículo científico publicado en 2015

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

artículo científico publicado en 2015

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

artículo científico publicado en 2014

NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations

artículo científico publicado en 2013

Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

artículo científico publicado en 2015

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study

artículo científico publicado en 2014

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

artículo científico publicado en 2017

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

artículo científico publicado en 2012

Reply: To PMID 25098971.

artículo científico publicado en 2015

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

artículo científico publicado en 2011

Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved ⬇️

artículo científico publicado el 27 de junio de 2011

Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey.

artículo científico publicado en 2013

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling

artículo científico publicado en 2014

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies

artículo científico publicado en 2016

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients

artículo científico publicado en 2014

Lista de obras de Jeremie Guedj

A pharmacokinetic/viral kinetic model to evaluate the treatment effectiveness of danoprevir against chronic HCV.

Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model

Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques

Antiviral efficacy of favipiravir against Zika and SARS-CoV-2 viruses in non-human primates

Association Between Tumor Size Kinetics and Survival in Patients With Urothelial Carcinoma Treated With Atezolizumab: Implication for Patient Follow-Up

COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models

Can we use viral kinetic models to individualize treatment?

Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Design evaluation and optimization for models of hepatitis C viral dynamics.

Designing a Pediatric Study for an Antimalarial Drug by Using Information from Adults

Determining Ribavirin's mechanism of action against Lassa virus infection

Dominance of the CD4(+) T helper cell response during acute resolving hepatitis A virus infection.

Dose regimen of favipiravir for Ebola virus disease

Early HIV RNA decay during raltegravir-containing regimens exhibits two distinct subphases (1a and 1b).

Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies

Ebola virus dynamics in mice treated with favipiravir

Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C.

Estimating biologically relevant parameters under uncertainty for experimental within-host murine West Nile virus infection.

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.

Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Impact of treatment against hepatitis C virus on overall survival of naive patients with advanced liver disease

Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection

Lassa viral dynamics in non-human primates treated with favipiravir or ribavirin

Mathematical modeling of bacterial kinetics to predict the impact of antibiotic colonic exposure and treatment duration on the amount of resistant enterobacteria excreted

Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?

Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life

Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients

Modelling hepatitis C therapy--predicting effects of treatment

Modelling the interaction between danoprevir and mericitabine in the treatment of chronic HCV infection.

Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.

NIMROD: a program for inference via a normal approximation of the posterior in models with random effects based on ordinary differential equations

Nonlinear Mixed-effect Models for Prostate-specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: A Comparison by Simulation of Two-stage and Joint Approaches.

Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: a retrospective clinical-pathological study

Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

Reply: To PMID 25098971.

Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.

Silibinin mode(s) of action against hepatitis C virus: A controversy yet to be resolved ⬇️

Umbilical artery Doppler assessment: a clear disparity in ultrasound practice in a national survey.

Understanding early serum hepatitis D virus and hepatitis B surface antigen kinetics during pegylated interferon-alpha therapy via mathematical modeling

Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients

Using vaccine Immunostimulation/Immunodynamic modelling methods to inform vaccine dose decision-making